Latest Content

A quick recap of the last week in psychiatric news.

FDA approves PET imaging agent for Alzheimer disease tau pathology.

Real‑world inpatient use of xanomeline/trospium shows rapid awakening from negative symptoms in schizophrenia, with response predictors and striking case insights.

Entactogen research targets social anxiety and isolation across diagnoses, pairing “plasticity windows” with psychotherapy amid shifting FDA scrutiny and evolving trial designs.

"...time slowed to the tide’s rhythm and the surf’s roar, each day closed by a Great Horned Owl’s silent fly-by at dusk..."

New data on viloxazine ER (Qelbree) show improvements in ADHD, depression, and anxiety in adults, including those who use nicotine or cannabis.

KINECT-PRO shows Ingrezza eases tardive dyskinesia movements and boosts daily function and quality of life, even across psychiatric diagnoses.

DT120 (lysergide) hits all endpoints in phase 3 GAD trial, cutting anxiety scores with a single dose.

Why modern psychiatry risks missing the person: It's time to revive biopsychosocial, cultural, and spiritual history beyond DSM checklists and EHR bloat.

Explore new consensus guidelines on childhood stuttering, uniting psychiatry and neurology with practical treatment insights to improve patient care.

Review the latest developments in narcolepsy treatment.

Review the latest in psychiatry from the last week.

STARS experts redefine stuttering as a brain-based neuropsychiatric disorder, urging interdisciplinary care and warning dopamine-boosting ADHD or antidepressant meds may worsen symptoms.